Valneva’s (VALN) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Valneva (NASDAQ:VALN) in a report issued on Wednesday, Benzinga reports. HC Wainwright currently has a $26.00 price target on the stock.

Separately, Guggenheim cut their price target on shares of Valneva from $18.00 to $17.00 and set a buy rating on the stock in a report on Friday, March 22nd.

Valneva Price Performance

NASDAQ:VALN opened at $7.24 on Wednesday. The firm has a market capitalization of $504.19 million, a price-to-earnings ratio of -4.58 and a beta of 2.22. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.65 and a quick ratio of 1.37. The business has a 50 day simple moving average of $7.68 and a 200-day simple moving average of $9.29. Valneva has a 1 year low of $6.58 and a 1 year high of $17.05.

Valneva (NASDAQ:VALN) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.70). Valneva had a negative return on equity of 59.48% and a negative net margin of 65.99%. The company had revenue of $45.12 million during the quarter, compared to the consensus estimate of $45.06 million. Equities analysts forecast that Valneva will post 0.11 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. lifted its stake in shares of Valneva SE (NASDAQ:VALN) by 2.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 354,361 shares of the company’s stock after acquiring an additional 9,361 shares during the quarter. General American Investors Co. Inc. owned approximately 0.51% of Valneva worth $2,831,000 at the end of the most recent reporting period. 11.39% of the stock is currently owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.